Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HRMY stock price vs VRSK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VRSK's multiple
Needs VRSK P/E.
Implied fair value · at HRMY's multiple
Needs HRMY P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HRMY FY 2025 (ended Dec 31, 2025) · VRSK FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 2.13x · EV / EBITDA 7.27x
Capital structure 79% equity / 21% debt · EV / Revenue 9.26x · EV / EBITDA 17.69x
VRSK carries the larger enterprise value at $28.45B against $1.85B; HRMY trades on the lower EV / Revenue multiple (2.13x vs 9.26x); HRMY on the lower EV / EBITDA (7.27x vs 17.69x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Verisk Analytics, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.19x
20.33x
Net debt / EBITDA
Leverage against operating earnings
-2.41x
2.55x
Cash and equivalents
Liquid reserves on the balance sheet
$775.34M
$2.18B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
HRMY vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
HRMY vs SUPN
Intra-Cellular Therapies, Inc.
HRMY vs ITCI
ACADIA PHARMACEUTICALS INC
HRMY vs ACAD
Vanda Pharmaceuticals Inc.
HRMY vs VNDA
LivaNova PLC
HRMY vs LIVN
Moody's Corporation
HRMY vs MCO
S&P Global Inc.
HRMY vs SPGI
CoreLogic, Inc.
HRMY vs CLGX
FACTSET RESEARCH SYSTEMS INC
HRMY vs FDS
$163.66M
$6.28B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
